Endonovo Therapeutics, Inc. Appoints Nevena Zubcevik as Chief Medical Officer, Effective July 1, 2019
May 02, 2019 at 02:20 pm
Share
Endonovo Therapeutics, Inc. announced the appointment of Nevena Zubcevik, DO, MSPT, ATC as its chief medical officer starting July 1, 2019. In her new role, Dr. Zubcevik will be in charge of medical and clinical strategy, including development and regulatory matters and new business development. That role will be increasingly important as Endonovo continues to develop its PEMF assets and the national roll-out of SofPulse. Dr. Zubcevik has over 24 years experience in the medical field, 17 of which are in clinical development, and is a licensed physician and educator. Prior to Endonovo, Dr. Zubcevik was an Attending Physician at Harvard Medical School/Partners HealthCare in the Physical Medicine and Rehabilitation Department. During her tenure at Harvard, Dr. Zubcevik was involved in innovation in both the clinical and research arenas, serving as a Principal Investigator to clinical trials and Clinical co-Director. She was also an Executive Director at LIV NGO, a non-profit organization.
Endonovo Therapeutics, Inc. is a biotechnology company. The Company is focused on developing bioelectronic devices and cell therapies for regenerative medicine and is a commercial-stage developer of non-invasive wearable Electroceuticals therapeutic devices. The Company's portfolio of commercial and clinical-stage wearable Electroceuticals therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome, and multiple sclerosis. Its non-invasive Electroceutical therapeutic device, SofPulse, uses pulsed short-wave radiofrequency at 27.12 megahertz (MHz) used for the palliative treatment of soft tissue injuries, and post-operative pain and edema, as well as for the treatment of chronic wounds. It offers an alternative, non-opioid treatment through its Electroceuticals systems.
ENDONOVO THERAPEUTICS, INC. 
